CO5640065A1 - Bacteria gram negativa atenuada - Google Patents
Bacteria gram negativa atenuadaInfo
- Publication number
- CO5640065A1 CO5640065A1 CO04111105A CO04111105A CO5640065A1 CO 5640065 A1 CO5640065 A1 CO 5640065A1 CO 04111105 A CO04111105 A CO 04111105A CO 04111105 A CO04111105 A CO 04111105A CO 5640065 A1 CO5640065 A1 CO 5640065A1
- Authority
- CO
- Colombia
- Prior art keywords
- mutant
- bacterium
- paragraph
- mutation
- pasteurella
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 7
- 230000035772 mutation Effects 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 4
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 241000606856 Pasteurella multocida Species 0.000 abstract 2
- 230000008030 elimination Effects 0.000 abstract 2
- 238000003379 elimination reaction Methods 0.000 abstract 2
- 229940051027 pasteurella multocida Drugs 0.000 abstract 2
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 241000606860 Pasteurella Species 0.000 abstract 1
- 241000606752 Pasteurellaceae Species 0.000 abstract 1
- 241001478212 Riemerella anatipestifer Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000002949 hemolytic effect Effects 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un mutante de una bacteria gram negativa, en donde dicha bacteria tiene una mutación en una secuencia de nucleótido que codifica para un polipéptido que tiene una identidad que es igual o mayor que 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% o 99% con una secuencia de aminoácido codificada por una secuencia de nucleótido selecciona del grupo que consiste de las secuencias de nucleótido identificadas como ID de Sec. No.: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93 dicha mutación resulta en virulencia atenuada de la bacteria.2.- El mutante del parágrafo 1, en donde la bacteria es una Pasteurellaceae.3.- El mutante del parágrafo 2 en donde la bacteria es escogida entre el grupo de: Pasteurella multocida, Pasteurella hemolítica, Pasteurella anatipestifer y Actinobacillus pleuropneumoniae.4.- El mutante del parágrafo 3, en donde la bacteria es Pasteurella multocida.5.- El mutante de una cualquiera de los parágrafos 1 a 4, en donde la mutación es una eliminación en la secuencia del nucleótido, o una inserción en esta o un reemplazo de ácidos nucleicos.6.- El mutante del parágrafo 5, en donde la mutación es la eliminación de la secuencia de nucleótido completa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37028202P | 2002-04-05 | 2002-04-05 | |
US10/406,686 US7449178B2 (en) | 2002-04-05 | 2003-04-03 | Attenuated gram negative bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5640065A1 true CO5640065A1 (es) | 2006-05-31 |
Family
ID=29254405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04111105A CO5640065A1 (es) | 2002-04-05 | 2004-11-04 | Bacteria gram negativa atenuada |
Country Status (16)
Country | Link |
---|---|
US (3) | US7449178B2 (es) |
EP (1) | EP1575483B1 (es) |
JP (1) | JP4338528B2 (es) |
KR (1) | KR101037566B1 (es) |
CN (2) | CN102864090A (es) |
AT (1) | ATE518955T1 (es) |
AU (2) | AU2003223447C1 (es) |
BR (1) | BRPI0309001B1 (es) |
CA (1) | CA2481186C (es) |
CO (1) | CO5640065A1 (es) |
ES (1) | ES2371498T3 (es) |
HK (1) | HK1078271A1 (es) |
MX (1) | MXPA04009730A (es) |
NZ (1) | NZ535993A (es) |
PT (1) | PT1575483E (es) |
WO (1) | WO2003086277A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996017951A2 (en) * | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
DK1108034T3 (da) * | 1998-09-04 | 2008-11-10 | Emergent Product Dev Uk Ltd | Svækkede salmonella SPI2-mutanter som antigenbærere |
GB9910812D0 (en) * | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
US7449178B2 (en) * | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
ES2320419T3 (es) * | 2002-04-05 | 2009-05-22 | Merial | Bacterias gram negativas atenuadas. |
CN1798574B (zh) | 2003-07-02 | 2013-12-11 | 生物技术研究与发展公司 | 无荚膜的多杀巴斯德氏菌hyaE缺失型突变株 |
JP4981684B2 (ja) | 2004-12-22 | 2012-07-25 | インターベツト・インターナシヨナル・ベー・ベー | パストゥレラ・マルトシダワクチン |
US8703153B2 (en) | 2008-06-16 | 2014-04-22 | Prokarium Ltd. | Salmonella vectored vaccines against Chlamydia and methods of use |
US8917497B2 (en) * | 2012-07-23 | 2014-12-23 | Knaack Llc | Jobsite storage cabinet for housing electronic equipment |
ES2824402T3 (es) | 2013-11-01 | 2021-05-12 | Boehringer Ingelheim Animal Health Usa Inc | Vacunas atenuadas contra Pasteurella multocida y procedimientos de fabricación y uso de las mismas |
CN107075562B (zh) * | 2014-09-30 | 2021-09-24 | 深圳华大基因科技有限公司 | 用于肥胖症相关疾病的生物标记物 |
TW202219269A (zh) * | 2020-09-30 | 2022-05-16 | 美國農業部 | 新型多殺性巴斯德氏菌株及具有hyaC與nanP缺失之疫苗 |
TW202214294A (zh) * | 2020-09-30 | 2022-04-16 | 美商碩騰服務公司 | 具有hyaC及nanP缺失之新穎多殺性巴斯德氏菌株及疫苗 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0668779A4 (en) * | 1992-11-06 | 1996-08-21 | Univ Minnesota | Vaccine to protect against pasteurellosis - infection by P.multocida. |
US6793927B1 (en) * | 1993-12-06 | 2004-09-21 | The United States Of America As Represented By The Secretary Of The Department Of Agriculture | Construction of Pasteurella haemolytica vaccines |
WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
HU226219B1 (en) * | 1996-05-31 | 2008-06-30 | Intervet Int Bv | Live attenuated rtx-producing bacteria of the family pasteurellaceae |
US6086894A (en) * | 1996-06-27 | 2000-07-11 | Virginia Tech Intellectual Properties, Inc. | Recombinant vaccine for diseases caused by encapsulated organisms |
US6783764B1 (en) * | 1997-04-10 | 2004-08-31 | Akzo Nobel Nv | Actinobacillus pleuropneumoniae subunit vaccine |
CH692179A5 (de) | 1997-06-25 | 2002-03-15 | Kueschall Design Ag | Rollstuhl und Sitzmodul für den Rollstuhl, |
US20010018055A1 (en) * | 1997-09-25 | 2001-08-30 | Briggs Robert E. | Deletion mutants of virulence factors of pasteurellaceae |
EP1860117A3 (en) * | 1999-04-09 | 2008-09-03 | Pharmacia & Upjohn Company LLC | Anti-bacterial vaccine compositions |
US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
GB9910812D0 (en) * | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
US6780405B1 (en) * | 2000-04-28 | 2004-08-24 | Avant Immunotherapeutics, Inc. | Regulated antigen delivery system (RADS) |
WO2002018601A2 (en) * | 2000-08-25 | 2002-03-07 | Abbott Laboratories | Essential bacteria genes and genome scanning in haemophilus influenzae for the identification of 'essential genes' |
US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
ES2320419T3 (es) * | 2002-04-05 | 2009-05-22 | Merial | Bacterias gram negativas atenuadas. |
US7449178B2 (en) * | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
CA2520386A1 (en) * | 2003-03-27 | 2004-10-14 | Children's Hospital, Inc. | Nontypeable haemophilus influenzae virulence factors |
UA100370C2 (uk) * | 2006-12-11 | 2012-12-25 | Мериал Лимитед | Спосіб вакцинації птахів проти salmonella |
TWI328458B (en) * | 2007-03-09 | 2010-08-11 | Univ Nat Chunghsing | Subunit vaccine of pasteurella multocida in veterinary uses |
-
2003
- 2003-04-03 US US10/406,686 patent/US7449178B2/en not_active Expired - Lifetime
- 2003-04-04 WO PCT/US2003/010308 patent/WO2003086277A2/en active Application Filing
- 2003-04-04 CN CN2011104311167A patent/CN102864090A/zh active Pending
- 2003-04-04 AU AU2003223447A patent/AU2003223447C1/en not_active Expired
- 2003-04-04 CN CNA038123800A patent/CN1934240A/zh active Pending
- 2003-04-04 KR KR1020047015890A patent/KR101037566B1/ko active IP Right Grant
- 2003-04-04 PT PT03719577T patent/PT1575483E/pt unknown
- 2003-04-04 AT AT03719577T patent/ATE518955T1/de active
- 2003-04-04 NZ NZ535993A patent/NZ535993A/en not_active IP Right Cessation
- 2003-04-04 MX MXPA04009730A patent/MXPA04009730A/es active IP Right Grant
- 2003-04-04 CA CA2481186A patent/CA2481186C/en not_active Expired - Lifetime
- 2003-04-04 EP EP03719577A patent/EP1575483B1/en not_active Expired - Lifetime
- 2003-04-04 JP JP2003583304A patent/JP4338528B2/ja not_active Expired - Lifetime
- 2003-04-04 BR BRPI0309001-9A patent/BRPI0309001B1/pt not_active IP Right Cessation
- 2003-04-04 ES ES03719577T patent/ES2371498T3/es not_active Expired - Lifetime
-
2004
- 2004-11-04 CO CO04111105A patent/CO5640065A1/es not_active Application Discontinuation
-
2005
- 2005-12-02 HK HK05111055.4A patent/HK1078271A1/xx not_active IP Right Cessation
-
2008
- 2008-10-07 US US12/246,809 patent/US7943125B2/en not_active Expired - Lifetime
-
2010
- 2010-08-04 AU AU2010206113A patent/AU2010206113B2/en not_active Expired
-
2011
- 2011-04-20 US US13/091,046 patent/US8329163B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5640065A1 (es) | Bacteria gram negativa atenuada | |
AR071888A2 (es) | Bacteria pasteurellaceae gram-negativa, una composicion inmunogena, una composicion para vacunas | |
PT87562A (pt) | Procede de expression de la proapolipoproteine a-i humaine | |
SG165157A1 (en) | Identification of genes | |
ATE452979T1 (de) | Herstellungsverfahren von 1,3-propandiol durch rekombinante organismen | |
MX9301013A (es) | Proceso para la produccion de amino acidos por fermentacion. | |
PE14391A1 (es) | Metodo y composicion para eliminar desde superficies, sustancias que contienen glicosido empleando endoglicosidasa del tipo ii | |
CY1106926T1 (el) | Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της | |
DE60229050D1 (de) | Verfahren zur herstellung von ascorbinsäurezwischenprodukten in wirtszellen | |
CO5640148A2 (es) | Agentes de alivio del dolor | |
MX170652B (es) | Tratamiento bacteriano para conservar la calidad del heno mediante el agregado de microorganismos del genero bacillus | |
ES2180138T3 (es) | Composicion de poliamina/acido organico insaturado para revestimientos de barrera. | |
BR9909346A (pt) | Segmento de ácido nucleico, vetor recombinante, célula hospedeira, composição, processos para detectar uma espécie de dna, uma célula bacteriana e infecção, para produzir ácido hialurÈnico e para criar uma vacina, sequência de ácido nucleico e de cdna, vacina e teste diagnóstico | |
BRPI0406477A (pt) | Composição, agente de tratamento de óleo, e, métodos de produção de uma composição e de tratamento de óleo | |
BR9911917A (pt) | Composições compreendendo análogos de gaba e cafeìna | |
ES2189472T3 (es) | Agente para el tratamiento de agua. | |
ES2167896T3 (es) | Cargas superficialmente modificadas, de tipo oxido o silicato y su empleo. | |
AR029622A1 (es) | Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec | |
DE60206498D1 (de) | Verfahren zur herstellung von d-pantothensäure und/oder deren salzen | |
ATE305044T1 (de) | Lgmd- gen kodierend für einer calcium abhängigen protease | |
DK1350796T3 (da) | Attenuerede gramnegative bakterier | |
BR0312770A (pt) | Detecção de microorganismos | |
BR0108096A (pt) | Método para manter ou melhorar a sìntese de mucinas | |
BR9915537A (pt) | Gene prv-1 e sua utilização | |
DE50100344D1 (de) | Verfahren zur Herstellung von substituierten 10-Chlor-phenoxaphosphinen oder 10-Brom-phenoxaphosphinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |